title: New developments in the treatment of ischemia/reperfusion injury.
abstract: Currently, the treatment of reperfusion following ischemia is primarily supportive. Preventative measures may help in combating the occurrence of ischemia, but minimizing the secondary damage that occurs with the onset of reperfusion would improve outcomes. In this review, using a Medline search, we have outlined the current knowledge with respect to the pathophysiology of this disease process and focused primarily on the basic science investigations of drugs, including natural therapies, which have shown potential. It is becoming increasingly clear that no one method or drug is the magic elixir that solely treats reperfusion injury due to the complex and interconnected processes involved.
authors.affiliation: Department of Medicine, McMaster University, Hamilton, ON, Canada.
authors.forename: H K
authors.initials: HK
authors.lastname: Ondiveeran
authors.forename: A
authors.initials: A
authors.lastname: Fox-Robichaud
mesh_terms: D057911:Angiotensin Receptor Antagonists; D000818:Animals; D065128:Endothelin Receptor Antagonists; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016166:Free Radical Scavengers / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D010102:Oxygen Inhalation Therapy; D054328:Proton Pump Inhibitors; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000628:therapy
chemical_list: D057911:Angiotensin Receptor Antagonists; D065128:Endothelin Receptor Antagonists; D004791:Enzyme Inhibitors; D016166:Free Radical Scavengers; D054328:Proton Pump Inhibitors; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists